Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT

https://doi.org/10.20996/1819-6446-2013-9-3-292-300

Full Text:

Abstract

Data on the problem of thromboembolic complications in non-valvular atrial fibrillation are presented. Peculiarities of anticoagulant therapy to prevent thromboembolic complications, the difficulties in drug choice and dosage adjustment are also discussed.

About the Authors

E. L. Dolgova
Saratov State Medical University named after V.I. Razumovsky, Saratov
Russian Federation


I. M. Sokolov
Saratov State Medical University named after V.I. Razumovsky, Saratov
Russian Federation


Yu. G. Shvarts
Saratov State Medical University named after V.I. Razumovsky, Saratov
Russian Federation


References

1. Lip G.Y, Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137:263–72.

2. Stewart S., Murphy N., Walker A. et al. Cost of an emerging epidemic an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286–92.

3. Patel MR for ROCKET AF Executive Steering Committee. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation 2010; 122 (Suppl 21):2217.

4. Wadelius M., Chen L.Y., Downes K. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005;5 (4):262–70

5. ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation. Eur Heart J 2010;31:2369–429.

6. Feinberg W.M., Cornell E.S., Nightingale S.D. et al. Stroke Prevention in Atrial Fibrillation Investigators Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke 1997;28:1101–6.

7. Kirchhof P., Auricchio A., Bax J. et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007;28:2803–17.

8. Friberg J., Buch P., Scharling H., Gadsbphioll N. et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666–72.

9. Levy S., Maarek M., Coumel P. et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation 1999; 99:3028–35.

10. Go A.S., Hylek E.M., Phillips K.A. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulations and Risk factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285(18):2370–5.

11. Lloyd-Jones D.M., Wang T.J., Leip E.P. et al. Lifetime risk for development of atrial fibrillation. the Framingham Heart Study. Circulation 2004;110:1042–46.

12. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009;373:155–66

13. Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285: 2864–70.

14. Hylek E.M., Go A.S., Chang Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019–26.

15. Petersen P., Boysen G., Godtfredsen J., et al. Placebo controlled, randomized trial of warfarin and apirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175–9.

16. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84:527–539.

17. Connolly S.J., Laupacis A., Gent M., et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349–55.

18. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255–62.

19. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505– 11.

20. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists’ Collaboration. BMJ 2002;324:71–86.

21. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–67.

22. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008; 39:1901–10.

23. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687–91.

24. Cleland J.G.F., Findlay I., Jafri S. et al. Warfarin/Aspirin Study in Heart Failure (WASH): A Randomized Trial Comparing Antithrombotic Strategies for Patients With Heart Failure. Am Heart J 2004; 148(1):157–64.

25. Fang V.C., Singer D.E., Chang Y. et al. Gender differences in the risk of ischemic stroke and peripheral embolizm in atrial fibrillation: the Anticoagulation and Risk factors in Atrial fibrillation (ATRIA) study. Circulation 2005; 112:1687–91.

26. The ACTIVE Writing Group Clopidogrel plus aspirin versus oral anticoagulation for atrialfibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet2006;367(9526):1903–12.

27. Plavix (clopidogrel). Summary of opinion. EMA/CHMP/740480/2010. Committee for medicinal products for human use (CHMP). 18 November 2010. Available at: http://www.ema.europa.eu/docs/ en_GB/document_library/Summary_of_opinion/human/000174/WC500099174.pdf. Date of access 16.06.2013.

28. Kropacheva E.S., Panchenko E.P. Compare the efficacy and safety of long-term therapy with warfarin and acenocoumarol in patients with atrial fibrillation. Klin Med 2005; (1):24–7. Russian (Кропачева Е.С., Панченко Е.П. Сравнение эффективности и безопасности длительной терапии варфарином и аценокумаролом у больных с мерцательной аритмией. Клиническая Медицина 2005; (1): 24–7)

29. Artanova E.L., Saleeva E.V., Sokolov I.M., Shvarc Ju.G. Features dose adjustment of warfarin in patients with atrial fibrillation, according to clinical factors. Rational Pharmacother Card 2011;7(4):442–6. Russian (Артанова Е.Л., Салеева Е.В., Соколов И.М., Шварц Ю.Г. Особенности подбора дозы варфарина у пациентов с фибрилляцией предсердий в зависимости от клинических факторов. РФК 2011;7(4): 442–6.

30. Yin Т., Miyata Т. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 — Rationale and perspectives. Thromb Res 2006;102(4):1345–9.

31. Schwarz U.I., Ritchie M.D., Bradford Y. et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358 (10):999–1008.

32. Sirotkina O.V., Ulitina A.S., Taraskina A.E. Allelic variants of the CYP2C9*2 and CYP2C9*3 gene cy- tochrome CYP2C9 in the population of St. Petersburg and their clinical significance in anticoagulation therapy with warfarin. Russian Cardiology Journal 2004;(6):24–31. Russian (Сироткина О.В., Улитина А.С., Тараскина А.Е. и др. Аллельные варианты CYP2C9*2 и CYP2C9*3 гена цитохрома CYP2C9 в популяции Санкт-Петербурга и их клиническое значение при антикоагулянтной терапии варфарином. Росс кардиол журн 2004;(6):24–31).

33. Giacomini KM, Brett CM, Altman RB et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007;81(3):328–45.

34. Takahashi H., Wilkinson G.R., Nutescu E.A. et al. Different contributions of polymorphismsin VKORC1 and CYP2C9 to intra-andinter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006;16(2):101–10.

35. Holbrook A.M., Pereira J.A., Labiris R. et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165 (10):1095–106.

36. Harrison L., Johnston M., Massicotte M.P., et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133–6.

37. Mahtani KR, Heneghan CJ, Nunan D et al. Optimal loading dose of warfarin for the initiation of oral anticoagulation . Cochrane Database Syst Rev. 2012 Dec 12;12:CD008685.

38. Crowther M.A., Ginsberg J., Kearon C. et al. A randomized trial comparing 5 mg and 10 mg warfarin l oading doses. Arch Intern Med 1999;159:46–8.

39. Hylek E.M., Singer D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897–902.

40. National guidelines for the diagnosis and treatment of atrial fibrillation. Cardiovascular Therapy and Prophylaxis 2005;4(4)1:1–42 (Национальные рекомендации по диагностике и лечению фибрилляции предсердий. Кардиоваскулярная Терапия и Профилактика 2005;4(4)1:1–42).

41. Olsson S.B. Executive Steering Committee of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003;362:1691–8.

42. Albers G.W., Diener H.C., Frison L. et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293:690–698.

43. Uchino K, Hernandez AV. Dabigatran Association With Higher Risk of Acute Coronary Events. Arch Intern Med 2012;172(5):397–402.

44. Gage B.F. Can we rely on RE-LY? N Engl J Med 2009;361:1200–2.

45. Wann L.S.,Curtis A.B., Ellenbogen K.A. et al. ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update of Dabigatran). A report of the American College of Cardiology Foundation /American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:1144–1150.

46. Southworth MR, Reichman ME, Unger EF. Dabigatran and Postmarketing Reports of Bleeding. N Engl J Med 2013; 368(14):1272–1273.

47. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806–17.

48. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. The Lancet Neurology; 11(6):503–11.

49. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883–91.


For citation:


Dolgova E.L., Sokolov I.M., Shvarts Yu.G. ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT. Rational Pharmacotherapy in Cardiology. 2013;9(3):292-300. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-3-292-300

Views: 577


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)